Andrew P. Cope

EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia

<scp>EULAR</scp> /American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia

Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial

Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study

The influence of safety warnings on the prescribing of JAK inhibitors

JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications

Rheumatoid arthritis prevention in arthralgia: fantasy or reality?

Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming

Management of gout following 2016/2017 European (EULAR) and British (BSR) guidelines: An interrupted time-series analysis in the United Kingdom

The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

LFA-1 in T cell priming, differentiation, and effector functions

EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis

Epidemiology of Scleritis in the United Kingdom From 1997 to 2018: Population‐Based Analysis of 11 Million Patients and Association Between Scleritis and Infectious and Immune‐Mediated Inflammatory Disease

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional study

Venous Thromboembolism Risk With JAK Inhibitors: A Meta‐Analysis

Diapedesis-Induced Integrin Signaling via LFA-1 Facilitates Tissue Immunity by Inducing Intrinsic Complement C3 Expression in Immune Cells

Mechanisms of checkpoint inhibition-induced adverse events

PET Imaging of Liposomal Glucocorticoids using ⁸⁹Zr-oxine: Theranostic Applications in Inflammatory Arthritis

Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial

A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis

Multi-color Molecular Visualization of Signaling Proteins Reveals How C-Terminal Src Kinase Nanoclusters Regulate T Cell Receptor Activation

A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol

Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Real world long-term impact of intensive treatment on disease activity, disability and health-related quality of life in rheumatoid arthritis

Placebo Response in Rheumatoid Arthritis Clinical Trials

Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes

Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients